Gemfibrozil
Gemfibrozil is a cholesterol and triglyceride medicine (a fibrate) used with diet to treat very high triglycerides and, in select people, to lower the risk of coronary heart disease.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 51 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Gemfibrozil is an older fibrate, on the market since about 1981 and available as a generic, used with diet for very high triglycerides and, in a narrow group, to lower coronary heart disease risk; it lowers triglycerides and VLDL (triglyceride-rich fat particles) and raises HDL, the “good” cholesterol. Most people tolerate it well, with indigestion, stomach pain or diarrhea the usual complaints. The one thing to watch for is muscle damage, so report muscle pain, tenderness or weakness right away, especially if you also take a statin. Ongoing belly pain deserves the same prompt call, since gallstones are more common on it.
Clinical pearls
- Take it twice a day, about 30 minutes before breakfast and dinner, not with the meal itself.
- Never combine it with simvastatin or repaglinide, which risk severe muscle and kidney damage or dangerously low blood sugar.
- If you take warfarin, expect a lower warfarin dose and more frequent blood clotting tests once gemfibrozil starts.
- Expect repeat lipid tests, because if your triglycerides do not improve meaningfully, the label says gemfibrozil should be stopped.
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾
BOXED WARNING
Read the full warning on DailyMed →Patient information guide A plain-language walkthrough of Gemfibrozil, written from its FDA label.
What Gemfibrozil is used for
▾
Gemfibrozil is used along with diet for these purposes:
- Gemfibrozil and Lopid tablets: treating adults with very high triglycerides (Types IV and V hyperlipidemia) who are at risk of pancreatitis and haven't responded enough to diet.
- Gemfibrozil and Lopid tablets: reducing the risk of coronary heart disease in Type IIb patients (low HDL, high LDL and high triglycerides) with no history or symptoms of coronary heart disease, after an inadequate response to weight loss, diet, exercise and other medicines.
How Gemfibrozil works
▾
Gemfibrozil is a lipid-regulating medicine. It lowers triglycerides and VLDL cholesterol and raises HDL cholesterol, including the HDL2 and HDL3 subtypes and related proteins.
Its effect on LDL cholesterol varies. It may drop modestly, stay about the same, or rise in people with very high triglycerides.
Gemfibrozil dosage
▾
Gemfibrozil tablets are taken by mouth, twice a day, 30 minutes before breakfast and dinner. Your prescriber chooses the dose, so follow your label. Keep following your diet while taking it.
Dosing details from the FDA-approved label
From the Gemfibrozil prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Adults
- 1200 mg administered in two divided doses 30 minutes before the morning and evening meals
- Given 30 minutes before the morning and evening meals
Read the label’s full dosing text
DOSAGE AND ADMINISTRATION The recommended dose for adults is 1200 mg administered in two divided doses 30 minutes before the morning and evening meals (see CLINICAL PHARMACOLOGY ). OVERDOSAGE There have been reported cases of overdosage with gemfibrozil. In one case, a 7-year-old child recovered after ingesting up to 9 grams of gemfibrozil. Symptoms reported with overdosage were abdominal cramps, abnormal liver function tests, diarrhea, increased CPK, joint and muscle pain, nausea and vomiting. Symptomatic supportive measures should be taken, should an overdose occur.
Read the full Dosage and Administration section on DailyMed →
Gemfibrozil side effects
▾
Digestive complaints were the most common side effects in studies.
Common side effects
- Indigestion (dyspepsia)
- Stomach pain
- Diarrhea
- Fatigue
- Nausea and vomiting
- Eczema or rash
- Vertigo (spinning dizziness)
- Constipation or headache
When to get medical help
- Muscle pain, tenderness or weakness, which can signal muscle damage (myositis or rhabdomyolysis). Get prompt medical evaluation.
- Symptoms of gallstones or gallbladder trouble, such as ongoing belly pain. Gemfibrozil should be stopped if gallstones are found.
- Severe or recurring abdominal pain, which may point to appendicitis or pancreatitis.
- Yellowing of the skin or eyes, or other signs of liver problems.
- Signs of a serious allergic reaction, such as swelling of the face or throat, hives, or trouble breathing.
- Unusual bleeding or bruising if you also take warfarin.
Gemfibrozil warnings and precautions
▾
- Gallstones and gallbladder disease: more common with gemfibrozil. It should be stopped if gallstones are found.
- Muscle damage: fibrates can cause myositis, and combining with statins raises the risk of rhabdomyolysis (muscle breakdown) and kidney failure.
- Limited benefit proof: a reduction in heart-disease deaths has not been shown, so it should only be used for the labeled groups.
- Liver and blood changes: abnormal liver tests and blood count changes have been reported.
- Appendicitis and abdominal surgery: more cases were seen in studies.
Gemfibrozil interactions
▾
Gemfibrozil can raise levels of other medicines and raise muscle risks.
- Simvastatin, repaglinide, dasabuvir and selexipag: not to be combined.
- Other statins: higher risk of muscle and kidney damage; avoid rosuvastatin if possible.
- Warfarin: dose usually needs reducing, with frequent clotting tests.
- Colchicine: higher muscle risk, especially in older adults or those with kidney problems.
- Enzalutamide and other CYP2C8 or OATP1B1 drugs: levels may rise, so doses may need lowering.
- Colestipol and similar resins: separate by at least 2 hours.
Interactions listed in the FDA-approved label
From the Gemfibrozil prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Simvastatin (HMG-CoA reductase inhibitor): Concomitant administration of gemfibrozil with simvastatin is contraindicated; the risk of myopathy and rhabdomyolysis is increased with combined gemfibrozil and HMG-CoA reductase inhibitor therapy. Contraindicated.
- Rosuvastatin: The risk of myopathy and rhabdomyolysis is increased with combined gemfibrozil and HMG-CoA reductase inhibitor therapy. Avoid concomitant use. If it cannot be avoided, initiate rosuvastatin at 5 mg once daily; the dose of rosuvastatin should not exceed 10 mg once daily.
- Warfarin (anti-coagulants): Caution should be exercised when warfarin is given with gemfibrozil, as bleeding complications can occur through the effect on prothrombin time. Reduce the warfarin dose to maintain the prothrombin time at the desired level; frequent prothrombin determinations are advisable until the prothrombin level has stabilized.
- CYP2C8 substrates (e.g., dabrafenib, enzalutamide, loperamide, montelukast, paclitaxel, pioglitazone, rosiglitazone): Gemfibrozil is a strong inhibitor of CYP2C8 and may increase exposure of drugs mainly metabolized by CYP2C8. Dosing reduction of drugs mainly metabolized by CYP2C8 may be required when used with gemfibrozil.
- Repaglinide: Co-administration with gemfibrozil resulted in an 8.1-fold higher repaglinide AUC and prolonged its hypoglycemic effects, increasing the risk of severe hypoglycemia. Contraindicated.
- Dasabuvir: Gemfibrozil increased dasabuvir AUC and Cmax (ratios: 11.3 and 2.01, respectively) due to CYP2C8 inhibition, which may increase the risk of QT prolongation. Contraindicated.
- Selexipag: Co-administration doubled exposure to selexipag and increased exposure to the active metabolite by approximately 11-fold. Contraindicated.
- Enzalutamide: After gemfibrozil 600 mg twice daily, the AUC of enzalutamide plus active metabolite increased 2.2 fold and Cmax decreased by 16%; increased exposure may increase the risk of seizures. If co-administration is considered necessary, the dose of enzalutamide should be reduced.
- OATP1B1 substrates (e.g., atorvastatin, rosuvastatin, pravastatin, glyburide, valsartan, rifampin): Gemfibrozil is an inhibitor of the OATP1B1 transporter and may increase exposure of drugs that are OATP1B1 substrates. Dosing reductions of OATP1B1 substrates may be required when used with gemfibrozil.
- Bile acid-binding resins (e.g., colestipol): Gemfibrozil AUC was reduced by 30% when given simultaneously with resin-granule drugs such as colestipol. Administer the drugs two hours or more apart.
Read the label’s full interactions text
3. Drug Interactions (A) HMG-CoA Reductase Inhibitors: The concomitant administration of gemfibrozil with simvastatin is contraindicated ( see CONTRAINDICATIONS and WARNINGS ). Avoid concomitant use of gemfibrozil with rosuvastatin. If concomitant use cannot be avoided, initiate rosuvastatin at 5 mg once daily. The dose of rosuvastatin should not exceed 10 mg once daily. The risk of myopathy and rhabdomyolysis is increased with combined gemfibrozil and HMG-CoA reductase inhibitor therapy. Myopathy or rhabdomyolysis with or without acute renal failure have been reported as early as three weeks after initiation of combined therapy or after several months (see WARNINGS ). There is no assurance that periodic monitoring of creatine kinase will prevent the occurrence of severe myopathy and kidney damage. (B) Anti-coagulants: CAUTION SHOULD BE EXERCISED WHEN WARFARIN IS GIVEN IN CONJUNCTION WITH GEMFIBROZIL. THE DOSAGE OF WARFARIN SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS. FREQUENT PROTHROMBIN DETERMINATIONS ARE ADVISABLE UNTIL IT HAS BEEN DEFINITELY DETERMINED THAT THE PROTHROMBIN LEVEL HAS STABILIZED. (C) CYP2C8 Substrates: Gemfibrozil is a strong inhibitor of CYP2C8 and may increase exposure of drugs mainly metabolized by CYP2C8 (e.g., dabrafenib, enzalutamide, loperamide, montelukast, paclitaxel, pioglitazone, rosiglitazone). Therefore, dosing reduction of drugs that are mainly metabolized by CYP2C8 enzyme may be required when gemfibrozil is used concomitantly (see WARNINGS ). Repaglinide: In healthy volunteers, co-administration with gemfibrozil (600 mg twice daily for 3 days) resulted in an 8.1-fold (range 5.5- to 15.0- fold) higher repaglinide AUC and a 28.6-fold (range 18.5- to 80.1-fold) higher repaglinide plasma concentration 7 hours after the dose.
Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Gemfibrozil
▾
- Do not use with liver disease, severe kidney disease or primary biliary cirrhosis.
- Do not use with existing gallbladder disease.
- Do not use if allergic to gemfibrozil.
- Share your full medicine list with your prescriber.
- Mention estrogen use and any thyroid problems or diabetes.
- Older adults and those with kidney problems face higher muscle risks with colchicine.
Gemfibrozil overdose
▾
Symptoms reported after overdose include abdominal cramps, diarrhea, nausea and vomiting, joint and muscle pain, abnormal liver tests and raised CPK. Treatment is symptom-based supportive care. Seek emergency help or call poison control if too much is taken.
What Gemfibrozil does in the body
▾
Gemfibrozil lowers triglycerides and VLDL cholesterol and raises HDL cholesterol. In the Helsinki Heart Study, it was linked to fewer serious coronary events over five years in men with high non-HDL cholesterol and no prior coronary heart disease. Overall death rates were similar to placebo during the trial.
How to store Gemfibrozil
▾
Store at controlled room temperature 20° – 25°C (68° – 77°F) . Protect from light and humidity.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Gemfibrozil
59 supplements and herbal products have documented interactions with Gemfibrozil in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 4
- Moderate · 46
- Minor · 9
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Nutrient depletion considerations
Gemfibrozil has been associated with lower levels of 1 nutrient in the clinical literature. This does not mean a deficiency will occur — it means these may be worth discussing with your pharmacist or healthcare provider, especially with long-term use.
Educational information from a licensed clinical database (Natural Medicines) — not medical advice. Do not start or stop medications or supplements without professional guidance.
Gemfibrozil: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Gemfibrozil — the kind of thing our pharmacy team would talk through with you at the counter.
What is gemfibrozil for?
▾
How should I take it?
▾
What side effects should I expect?
▾
When should I call my doctor?
▾
Can I take it with my other medicines?
▾
Who shouldn't take gemfibrozil?
▾
Is Gemfibrozil available over the counter?
▾
When was Gemfibrozil first available?
▾
Who makes Gemfibrozil?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Gemfibrozil on HelloPharmacist
Gemfibrozil forms and strengths (how it comes)
Gemfibrozil is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Gemfibrozil inactive ingredients by manufacturer.
Tablet
How this form is used
- Gemfibrozil and Lopid tablets are used with diet for very high triglycerides (Types IV and V hyperlipidemia) in adults at risk of pancreatitis.
- Gemfibrozil and Lopid tablets are used to reduce the risk of coronary heart disease in select Type IIb patients without existing coronary heart disease.
- Gemfibrozil and Lopid tablets are taken by mouth in two divided doses each day.
- Gemfibrozil and Lopid tablets are taken 30 minutes before the morning and evening meals.
Gemfibrozil on the U.S. market: products, makers and brands
How Gemfibrozil appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
26 companies list 44 Gemfibrozil product records with the FDA, mostly as tablet; the earliest marketing or approval year on record is 1981. Brand names on the directory include Lopid; the rest are generics.
Also listed with the FDA, not a patient dose form: Powder (4) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Gemfibrozil is used (Medicaid data)
A general measure of how commonly Gemfibrozil is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Gemfibrozil is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Gemfibrozil prescribed? Of the 1,601 medications we measure, Gemfibrozil ranks #366 by Medicaid prescriptions — more than 77% of them.
Utilization by Gemfibrozil product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
gemfibrozil 600 MG Oral Tablet
Summed across the 15 of 216 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 310459
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Gemfibrozil, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 15 of 216 listed Gemfibrozil NDCs with Medicaid activity.
Compare Gemfibrozil products
A representative set of FDA-listed product records for Gemfibrozil — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Tablet | ||||
| 600 mg | Oral | A-S Medication Solutions × 6 listings | ANDA | View NDC → |
| 600 mg | Oral | American Health Packaging | ANDA | View NDC → |
| 600 mg | Oral | Aphena Pharma Solutions - Tennessee, LLC × 4 listings | ANDA | View NDC → |
| 600 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 600 mg | Oral | AvPAK | ANDA | View NDC → |
| 600 mg | Oral | Bryant Ranch Prepack × 5 listings | ANDA | View NDC → |
| 600 mg | Oral | Cadila Pharmaceuticals Limited | ANDA | View NDC → |
| 600 mg | Oral | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| 600 mg | Oral | Chartwell RX, LLC | ANDA | View NDC → |
| 600 mg | Oral | Cipla USA Inc. | ANDA | View NDC → |
| 600 mg | Oral | Coupler LLC | ANDA | View NDC → |
| 600 mg | Oral | Exelan Pharmaceuticals, Inc. | ANDA | View NDC → |
| 600 mg | Oral | NCS HealthCare of KY, LLC dba Vangard Labs | ANDA | View NDC → |
| 600 mg | Oral | Northstar RxLLC | ANDA | View NDC → |
| 600 mg | Oral | NorthStar Rx LLC | ANDA | View NDC → |
| 600 mg | Oral | Northwind Health Company, LLC | ANDA | View NDC → |
| 600 mg | Oral | NuCare Pharmaceuticals, Inc. | ANDA | View NDC → |
| 600 mg | Oral | NuCare Pharmaceuticals,Inc. × 2 listings | ANDA | View NDC → |
| 600 mg | Oral | Parke-Davis Div of Pfizer Inc | NDA | View NDC → |
| 600 mg | Oral | PD-Rx Pharmaceuticals, Inc. | ANDA | View NDC → |
| 600 mg | Oral | Preferred Pharmaceuticals, Inc. | ANDA | View NDC → |
| 600 mg | Oral | Proficient Rx LP × 2 listings | ANDA | View NDC → |
| 600 mg | Oral | Remedyrepack Inc. × 3 listings | ANDA | View NDC → |
| 600 mg | Oral | Rising Pharma Holdings, Inc. | ANDA | View NDC → |
| 600 mg | Oral | Viona Pharmaceuticals Inc | ANDA | View NDC → |
| 600 mg | Oral | XLCare Pharmaceuticals, Inc. | ANDA | View NDC → |
| 600 mg | Oral | Zydus Lifesciences Limited | ANDA | View NDC → |
| 600 mg | Oral | Zydus Pharmaceuticals (USA) Inc. | ANDA | View NDC → |
Showing 44 of 44 products — FDA National Drug Code Directory. See every product, package size and price: browse all 44 Gemfibrozil NDCs →
Gemfibrozil side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Gemfibrozil — a signal of what to watch for, not proof the drug caused it.
The effects most often named in FDA reports that mention Gemfibrozil are nausea, fatigue, diarrhoea; about 67% of the reports were classed as serious. These are voluntary reports, so they show what people report, not how often it happens.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Gemfibrozil in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Gemfibrozil FDA approval history
How Gemfibrozil went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Gemfibrozil was first approved by the FDA in 1981 (Brand: LOPID · Pfizer Pharms); the first generic version was approved in 1993. It remains available in U.S. pharmacies today.
Source: Drugs@FDA.
Gemfibrozil recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Gemfibrozil recalls since July 2021.
✅No Gemfibrozil recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 4719 2 dose forms · 2 strengths
-
Dose form (SCDF) Oral Capsule RxCUI 372299No current FDA listingClinical drug / strength (SCD) 300 MGRxCUI 315106 -
Dose form (SCDF) Oral Tablet RxCUI 372300In current FDA listingsClinical drug / strength (SCD) 600 MGRxCUI 310459
Look up RxCUI 4719 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Gemfibrozil supply and shortage status
Whether Gemfibrozil is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Gemfibrozil is not in shortage right now; the FDA has 1 past shortage record for it.
✅No current shortage of Gemfibrozil on recordRead the full Gemfibrozil shortage page — affected NDCs, other makers, and what to do →
Source: openFDA, from the FDA Drug Shortages database.
💵 What Gemfibrozil costs pharmacies (NADAC benchmark)
The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.
| Form | Strength | Pharmacy acquisition benchmark | |
|---|---|---|---|
| Tablet · Oral | 600 mg | $0.104 per tablet | NDC details & price history |
| Tablet, Film Coated | 600 mg | $0.104 per tablet | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.
Gemfibrozil brand names
Gemfibrozil is sold under one brand name in the FDA directory — Lopid. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Gemfibrozil: manufacturers and labelers
26 companies list Gemfibrozil products with the FDA. By number of product records, the largest are A-S Medication Solutions, Bryant Ranch Prepack, Aphena Pharma Solutions - Tennessee, LLC. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
…and 2 more on the FDA NDC directory.
Gemfibrozil drug class (RxNorm)
Gemfibrozil belongs to the Peroxisome Proliferator-activated Receptor alpha Agonist class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Gemfibrozil page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Parke-Davis Div of Pfizer Inc is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →